✦ LIBER ✦

Toxicity, pharmacokinetics and metabolism of iododoxorubicin in cancer patients

✍ Scribed by Mross, Klaus; Mayer, Ulrich; Langenbuch, Tobias; Hamm, Kirsten; Burk, Konrad; Hossfeld, Dieter

Book ID: 122808689
Publisher: Elsevier Science
Year: 1990
Weight: 930 KB
Volume: 26
Category: Article
ISSN: 0277-5379
DOI: 10.1016/0277-5379(90)90276-Y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics and metabolism of forme

Pharmacokinetics and metabolism of formestane in breast cancer patients

✍ Per Eystein Lønning; Jürgen Geisler; Dag Clement Johannessen; Hans-Peter Gschwin 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 192 KB

Pharmacokinetics and metabolism of pirar

Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients

✍ Robert, J.; David, M.; Huet, S.; Chauvergne, J. 📂 Article 📅 1988 🏛 Elsevier Science ⚖ 577 KB

Disposition, pharmacokinetics, and metab

Disposition, pharmacokinetics, and metabolism of 14C-fotemustine in cancer patients

✍ Ings, R.M.J.; Gray, A.J.; Taylor, A.R.; Gordon, B.H.; Breen, M.; Hiley, M.; Brow 📂 Article 📅 1990 🏛 Elsevier Science ⚖ 608 KB

Pharmacokinetics and toxicity of continu

Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients

✍ Guy G. Chabot; Richard Pazdur; Frederick A. Valeriote; Laurence H. Baker 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 477 KB

Pharmacokinetics and metabolism of medro

Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer

✍ E. Utaaker; S. Lundgren; S. Kvinnsland; A. Aakvaag 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 495 KB

Subcutaneous recombinant gamma interfero

Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects

✍ John A. Thompson; W. Welby Cox; Catherine G. Lindgren; Carolyn Collins; Kathryn 📂 Article 📅 1987 🏛 Springer-Verlag 🌐 English ⚖ 750 KB

Recombinant gamma interferon (ry-IFN) was administered s. c. daily to 26 patients with advanced cancer. Patients were assigned to one of six doses: 0.5, 1, 2, 4, 6, or 8 million units (MU)/m 2 per d. The major toxicities were an influenza-like syndrome and fever, seen in all patients. Dose limiting